Preparation of MnO2@poly-(DMAEMA-co-IA)-conjugated methotrexate nano-complex for MRI and radiotherapy of breast cancer application

Abstract

A novel e cient pH-sensitive targeted magnetic resonance imaging (MRI) contrast agent and innovative radiosensitizing system were synthesized based on MnO 2 NPs coated with biocompatible poly (dimethylaminoethyl methacrylate -Co-itaconic acid) and targeted with methotrexate. The established NPs were characterized and MRI signal enhancement, relaxivity, cell targeting, toxicity, and radiotherapy e cacy were evaluated.The developed system displayed pH-responsive MRI contrast enhancement, differential uptake in malignant and normal cells, negligible in vitro cytotoxicity, and suitable in vitro cell targeting ability.Enhanced therapeutic e cacy in hypoxic conditions con rmed the e ciency of the system in MR imaging and radiation therapy of hypoxia cells.

Nanocarriers for methotrexate delivery/codelivery in the frame of cancer diagnostics and treatment: a review

“…Amphiphilic cross-linked poly(vinyl alcohol-methyl methacrylate) (PVA-PMMA) copolymer NPs (NPs) as pH-responsive system were fabricated to load MTX. It was shown that 47.24% and 65.39% of the drug were released at pH = 7.4 and pH = 5.8, respectively, after 96 h. MTT assay confirmed the effectiveness of NPs against MCF-7 cells (Ziyaee et al, 2023). improved water solubility, biocompatibility, high stability, and tunable surface modification properties (Li et al, 2010).…”

“…MnO 2 NPs coated with biocompatible poly(dimethyl-aminoethyl methacrylate-Co-itaconic acid) (DMAEMA-Co-IA)conjugated MTX were prepared based on pH-sensitive targeted magnetic resonance imaging (MRI) contrast agent and innovative radio-sensitizing system. MTT assay for MnO 2 @Poly(DMAEMA-Co-IA)-MTX NPs showed higher inhibitory effect on MCF-7 cell viability as compared to free MTX after 24 and 48 h with insignificant hemolytic activity (Ziyaee et al, 2023).…”